当前位置： SCI文献检索 > JOURNAL OF THROMBOSIS AND THROMBOLYSIS期刊下所有文献 > Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.

Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.

Abstract：

:C-reactive protein (CRP) is an independent predictor of risk in ACS patients, and it has been previously shown that percutaneous coronary intervention (PCI) is associated with an early rise in CRP. To assess the long-term relationship between PCI and CRP, we compared CRP levels at baseline, 30 days, 4 months and 24 months among patients in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial who were treated with PCI and those who did not receive PCI. At study entry, CRP was significantly higher among patients who had undergone PCI (13.2 vs. 9.5 mg/l, P < 0.001). However, by day 30 CRP was significantly lower among patients who had undergone PCI for management of the index event (1.5 vs. 2.1 mg/l, P < 0.001) and remained lower at 4 months and by end of study (average 2 years after ACS). Using a multivariable model, we observed that PCI was associated with 8.6% lower CRP level at month 4 (P = 0.05) and 14.2% at approximately 2 years (P = 0.0028). These analyses suggest that although PCI may acutely increase inflammation, it may also serve a role in decreasing inflammation associated with atherosclerotic plaques via long-term mechanical stabilization.

journal_name

J Thromb Thrombolysis

journal_title

Journal of thrombosis and thrombolysis

authors

Ray KK,Nazer B,Cairns R,Michael Gibson C,Cannon CP

doi

10.1007/s11239-010-0463-7

subject

Has Abstract

pub_date

2010-07-01 00:00:00

pages

10-3

issue

1

eissn

0929-5305

issn

1573-742X

journal_volume

30

pub_type

杂志文章,随机对照试验

相关文献

JOURNAL OF THROMBOSIS AND THROMBOLYSIS文献大全
  • Exposure to platelets promotes functional properties of endothelial progenitor cells.

    abstract：:Recent evidence indicates that endothelial progenitor cells (EPCs) have an important role in the process of repair following vascular injury, and that platelets mediate their recruitment to sites of injury. Platelets and EPCs can interact and bind directly. However, there is limited information on the effect of platel...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-010-0514-0

    authors： Leshem-Lev D,Omelchenko A,Perl L,Kornowski R,Battler A,Lev EI

    更新日期：2010-11-01 00:00:00

  • Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.

    abstract：:Warfarin is dependent on multiple hepatic enzymes for metabolism while apixaban is a substrate for P-glycoprotein (P-gp) transport and hepatic CYP3A4 metabolism. The aim of this analysis was to assess the impact of interacting medication use on the treatment effects of apixaban versus warfarin. Outcomes were compared ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s11239-019-01823-y

    authors： Washam JB,Hohnloser SH,Lopes RD,Wojdyla DM,Vinereanu D,Alexander JH,Gersh BJ,Hanna M,Horowitz J,Hylek EM,Xavier D,Verheugt FWA,Wallentin L,Granger CB,ARISTOTLE Committees and Investigators.

    更新日期：2019-04-01 00:00:00

  • Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients.

    abstract：:Data comparing the patient characteristics, management and outcomes for dabigatran versus warfarin major bleeding in the practice setting are limited. We performed a retrospective single health system study of atrial fibrillation patients with dabigatran or warfarin major bleeding from October 2010 through September 2...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-015-1213-7

    authors： Smythe MA,Forman MJ,Bertran EA,Hoffman JL,Priziola JL,Koerber JM

    更新日期：2015-10-01 00:00:00

  • Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism.

    abstract：:Recent gene knockout studies on mice have shown the role of toll-like receptor 9 (TLR9) in resolution of venous thromboembolism (VTE) through sterile inflammation. However, the role of a putative functional TLR9 polymorphism (rs5743836) in risk assessment of VTE recurrence remains unknown. The aim of our study was to ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s11239-017-1491-3

    authors： Ahmad A,Sundquist K,Zöller B,Svensson PJ,Sundquist J,Memon AA

    更新日期：2017-07-01 00:00:00

  • Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study.

    abstract：:Venous ulcers are the most severe manifestation of post-thrombotic syndrome (PTS). We have previously demonstrated that formation of compact fibrin clots resistant to lysis is observed in patients following deep-vein thrombosis (DVT) who developed PTS. The current study investigated whether unfavourable fibrin clot pr...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-01914-w

    authors： Polak MW,Siudut J,Plens K,Undas A

    更新日期：2019-11-01 00:00:00

  • Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

    abstract：:Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists. No specific reversal agent for factor Xa (FXa) direct inhibitors is currently available for clinical use. A modified activated human FXa decoy protein, andexan...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-018-1617-2

    authors： Sartori M,Cosmi B

    更新日期：2018-04-01 00:00:00

  • Aspirin resistance and genetic polymorphisms.

    abstract：:Differences in genetic makeup or polymorphisms can affect individual drug response. Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and improve clinical outcomes. The data are replete relative to the therap...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1023/a:1022066305399

    authors： Cambria-Kiely JA,Gandhi PJ

    更新日期：2002-08-01 00:00:00

  • Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

    abstract：:Among atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), rivaroxaban with background antiplatelet therapy significantly reduced the first occurrence of bleeding compared to triple therapy with warfarin. This study hypothesized that total bleeding events, including those beyond the f...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s11239-018-1703-5

    authors： Chi G,Yee MK,Kalayci A,Kerneis M,AlKhalfan F,Mehran R,Bode C,Halperin JL,Verheugt FWA,Wildgoose P,van Eickels M,Lip GYH,Cohen M,Peterson ED,Fox KAA,Gibson CM

    更新日期：2018-10-01 00:00:00

  • Renal Vein Thrombosis and Selective Arterial or Venous Thrombolytic Therapy.

    abstract：:Background: Renal vein thrombosis (RVT) complicating the nephrotic syndrome is associated with a poor prognosis. Methods/Results: RVT was diagnosed in 12 of 60 patients with a diagnosis of nephrotic syndrome suggested by computed tomography (CT) and subsequently confirmed by selective renal angiography. Fifty patients...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF00226414

    authors： Wu ZL,Zhou KR,Liao Lt

    更新日期：1996-01-01 00:00:00

  • Using big data to retrospectively validate the COMPASS-CAT risk assessment model: considerations on methodology.

    abstract：:External validation is a prerequisite in order for a prediction model to be introduced into clinical practice. Nonetheless, methodologically intact external validation studies are a scarce finding. Utilization of big datasets can help overcome several causes of methodological failure. However, transparent reporting is...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02191-8

    authors： Nikolakopoulos I,Nourabadi S,Eldredge JB,Anand L,Zhang M,Qiu M,Rosenberg D,Spyropoulos AC

    更新日期：2021-01-01 00:00:00

  • Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment.

    abstract：:Kuperman et al. found that patients with anemia had a higher risk of major bleeding (RR 2.84; 95% CI 2.52-3.39) in RIETE database. Anemia appeared to be an independent predictive factor for major bleeding [hazard ratio (HR) 1.95; 95% CI 1.72-2.20] in this registry. Unfortunately, selection bias due to enrolled patient...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 信件,多中心研究

    doi：10.1007/s11239-018-1668-4

    authors： Gaboreau Y,Zenatti N,Vermorel C,Imbert P,Bosson JL,Pernod G

    更新日期：2018-07-01 00:00:00

  • Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.

    abstract：:Patients with heparin-induced thrombocytopenia (HIT) type II require anticoagulation with non-heparin immediate acting anticoagulants. Danaparoid may cross react with HIT-antibodies and lepirudin may generate anti-lepirudin antibodies influencing anticoagulation. We hypothesised, that the synthetic small molecular thr...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-005-0942-4

    authors： Harenberg J,Jörg I,Fenyvesi T,Piazolo L

    更新日期：2005-02-01 00:00:00

  • Plasminogen deficiency.

    abstract：:Plasminogen plays an important role in fibrinolysis as well as wound healing, cell migration, tissue modeling and angiogenesis. Congenital plasminogen deficiency is a rare autosomal recessive disorder that leads to the development of thick, wood-like pseudomembranes on mucosal surfaces, mostly seen in conjunctivas nam...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-016-1416-6

    authors： Celkan T

    更新日期：2017-01-01 00:00:00

  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials.

    abstract：:This article focuses on lessons learned from clinical trials of antiplatelet therapies-in particular, that the degree of inhibition of ex vivo platelet aggregation does not necessarily directly translate into clinical efficacy. As an example, the case of the oral platelet glycoprotein IIb/IIIa inhibitors is presented,...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-007-0160-3

    authors： Steinhubl SR,Schneider DJ,Berger PB,Becker RC

    更新日期：2008-08-01 00:00:00

  • Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.

    abstract：:A 64-year-old man first developed ligneous conjunctivitis at the age of 58 years after right pulmonary resection because of suspected cancer; otherwise, he had been healthy. Since then, he began to suffer from various forms of chronic pseudomembranous mucositis. Laboratory tests demonstrated that he had 7.8 % of plasm...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-016-1375-y

    authors： Osaki T,Souri M,Song YS,Izumi N,Law R,Ichinose A

    更新日期：2016-08-01 00:00:00

  • The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro.

    abstract：:We assessed the effect of the intercellular mediator of inflammation, platelet activating factor (PAF), on platelet function. The interaction between PAF and the platelet agonists ADP, thrombin and convulxin was analyzed in vitro in whole blood with the use of flow cytometry and was further characterized with the use ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-008-0239-5

    authors： Keating FK,Schneider DJ

    更新日期：2009-07-01 00:00:00

  • Antithrombin after cardiac surgery: implications on short and mid-term outcome.

    abstract：BACKGROUND:Antithrombin (AT) drop during cardiac surgery has been described. The causes and the effects of this phenomenon are not clear. The objective of the study is to evaluate the relationship of AT postoperative values on short and mid-term outcome after cardiac surgery. METHODS:Between January and June 2005, 405...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-007-0191-9

    authors： Paparella D,Cappabianca G,Scrascia G,Fiore G,Paramythiotis A,Di Bari N,Liuzzi MP,Ibrahim MF,Fiore T,de Luca Tupputi Schinosa L

    更新日期：2009-01-01 00:00:00

  • Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

    abstract：:The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. Th...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-014-1140-z

    authors： Crowley MP,Quinn S,Coleman E,Eustace JA,Gilligan OM,O'Shea SI

    更新日期：2015-02-01 00:00:00

  • Mild hypothermia markedly reduces ischemia related coronary t-PA release.

    abstract：:In experimentally induced myocardial ischemia, mild hypothermia (33-35 degrees C) has a robust cardioprotective effect. Tissue plasminogen activator (t-PA) is a profibrinolytic enzyme that is released from the vascular endothelial cells in response to ischemia and other injurious stimuli. t-PA has also been found to h...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-009-0350-2

    authors： van der Pals J,Götberg M,Olivecrona GK,Brogren H,Jern S,Erlinge D

    更新日期：2010-04-01 00:00:00

  • Acute Myocardial Infarction in Canada: New Epidemiologic Insights on Incidence, Therapy, and Risk.

    abstract：:Objective: To define the changing incidence, risk, and therapy of acute myocardial infarction (A311). Data sources: Review of contemporary AMI data from the University of Alberta Hospitals, six other sites of the Clinical Quality Improvement Network (CQIN), and other Canadian and international centers. Data synthesis:...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF00132402

    authors： Montague T,Montague P,Barnes M,Taylor L,Wowk L,Fassbender K,Ackman M,Martin S,Armstrong PW,Teo K

    更新日期：1996-01-01 00:00:00

  • Thrombolytic therapy in pregnancy.

    abstract：:Pregnancy due to its physiological changes is a procoagulant state. The rate of cardiac valve prosthesis thrombosis, deep venous thrombosis and pulmonary embolism are all increased. Thrombolytic therapy with tissue plasminogen activator (rt-PA) is an approved therapy for ischemic stroke, myocardial infarction, pulmona...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-006-5709-z

    authors： Leonhardt G,Gaul C,Nietsch HH,Buerke M,Schleussner E

    更新日期：2006-06-01 00:00:00

  • Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable

    abstract：:Amlodipine, commonly used for relief of ischemic symptoms in coronary artery disease (CAD), may affect clopidogrel-induced antiplatelet effects. It remains unknown if ranolazine, an antianginal drug that constitutes a pharmacologic alternative to calcium channel blockade, interferes with clopidogrel-induced antiplatel...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11239-015-1203-9

    authors： Pelliccia F,Greco C,Gaudio C,Rosano G,Vitale C,Marazzi G,Rollini F,Angiolillo DJ

    更新日期：2015-10-01 00:00:00

  • Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report.

    abstract：:The outbreak of 2019 novel coronavirus disease (COVID-19) began since early December 2019, and has been declared as a public health emergency by the World Health Organization. Due to the hypercoagulable state, blood stasis and endothelial injury, severe patients with COVID-19 are at high risk for thrombosis. We report...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02084-w

    authors： Zhou B,She J,Wang Y,Ma X

    更新日期：2020-07-01 00:00:00

  • Eptifibatide-induced thrombocytopenia.

    abstract：:Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical litera...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-007-0166-x

    authors： Refaat M,Smith AJ,Edmundowicz D

    更新日期：2008-04-01 00:00:00

  • The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

    abstract：:According to our personal experience and to the study of the literature, 11 cases of venous thrombosis have been described as sporadic reports in patients with severe (homozygous) factor XII (FXII) deficiencies. In every cases but 4, associated risk factors were found to be present (pregnancy, post-partum period, surg...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1023/B:THRO.0000037670.42776.cd

    authors： Girolami A,Randi ML,Gavasso S,Lombardi AM,Spiezia F

    更新日期：2004-04-01 00:00:00

  • Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

    abstract：:There is a significantly increased risk of pregnancy complications in women with anti-phospholipid syndrome (APS). The risk is further heightened in those with previous arterial or venous thromboembolism and so-called 'triple positivity' for anti-phospholipid antibodies (i.e., when lupus anticoagulant, and anti-cardio...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-014-1080-7

    authors： Rose HL,Ho WK

    更新日期：2014-11-01 00:00:00

  • Prevalence of common hereditary risk factors for thrombophilia in Somalia and identification of a novel Gln544Arg mutation in coagulation factor V.

    abstract：:Thrombophilia, commonly manifested as venous thromboembolism (VTE), is a worldwide concern but little is known on its genetic epidemiology in many parts of the globe particularly in the developing countries. Here we employed TaqMan genotyping and pyrosequencing to evaluate the prevalence of known common nucleotide pol...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-017-1543-8

    authors： Abdi AA,Osman A

    更新日期：2017-11-01 00:00:00

  • A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocard

    abstract：:Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. an...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/a:1008872031770

    authors： Serebruany VL,Jang IK,Giugliano RP,Massey TJ,Schwarz Jr RP

    更新日期：1998-01-01 00:00:00

  • Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves.

    abstract：:Patients with mechanical heart valves (MHV) undergoing invasive procedures often receive periprocedural bridging with low-molecular-weight heparin (LMWH). The bridging strategies used in real-life and the predictors for bleeding and thrombosis are not well studied. We retrospectively assessed patients with MHV that un...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s11239-015-1216-4

    authors： Schulman JM,Majeed A,Mattsson E,Schulman S,Holmström M,Ågren A

    更新日期：2015-11-01 00:00:00

  • The pharmacology of novel oral anticoagulants.

    abstract：:Anticoagulation for the prevention of stroke is an important aspect of the management of atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran have emerged as important therapeutic treatment options for prevention of stroke i...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-013-0967-z

    authors： DeWald TA,Becker RC

    更新日期：2014-01-01 00:00:00